Veracyte Company Profile (NASDAQ:VCYT)

About Veracyte

Veracyte logoVeracyte, Inc. is a molecular diagnostics company. The Company is engaged in developing and delivering genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early-stage in patient care. The Company targets diseases in which various patients undergo diagnostic procedures that could be avoided with diagnosis from a cytology sample taken preoperatively. It operates in the United States. The Company's commercial solution, the Afirma Thyroid fine needle aspiration (FNA) Analysis is its offering for thyroid nodule assessment. The solution centers on its Afirma Gene Expression Classifier to resolve indeterminate FNA results, based on cytopathology, so that patients whose nodules are benign can avoid unnecessary diagnostic surgery and undergo routine monitoring instead. The Company's pulmonology product is designed to identify idiopathic pulmonary fibrosis, among patients presenting with a suspected interstitial lung disease.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VCYT
  • CUSIP:
Key Metrics:
  • Previous Close: $7.44
  • 50 Day Moving Average: $6.04
  • 200 Day Moving Average: $5.44
  • 52-Week Range: $4.21 - $8.15
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.44
  • P/E Growth: 0.00
  • Market Cap: $207.31M
  • Outstanding Shares: 27,864,000
  • Beta: 2.13
  • Net Margins: -70.10%
  • Return on Equity: -82.26%
  • Return on Assets: -48.57%
  • Debt-to-Equity Ratio: 0.73%
  • Current Ratio: 4.00%
  • Quick Ratio: 3.71%
Additional Links:
Companies Related to Veracyte:

Analyst Ratings

Consensus Ratings for Veracyte (NASDAQ:VCYT) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.80 (31.72% upside)

Analysts' Ratings History for Veracyte (NASDAQ:VCYT)
DateFirmActionRatingPrice TargetDetails
9/8/2016Cantor FitzgeraldSet Price TargetBuy$13.00View Rating Details
8/4/2016Piper Jaffray Cos.Reiterated RatingOverweight$12.00 -> $10.00View Rating Details
6/23/2016Leerink SwannReiterated RatingBuyView Rating Details
6/13/2016BTIG ResearchReiterated RatingBuy$10.00View Rating Details
11/19/2015StephensReiterated RatingBuyView Rating Details
10/14/2015Cowen and CompanyLower Price TargetOutperform$12.00 -> $8.00View Rating Details
3/22/2015William BlairReiterated RatingOutperformView Rating Details
3/20/2015Morgan StanleyReiterated RatingEqual Weight$9.00View Rating Details
11/14/2014Janney Montgomery ScottDowngradeBuy -> Neutral$11.00View Rating Details
(Data available from 9/30/2014 forward)


Earnings History for Veracyte (NASDAQ:VCYT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2016Q216($0.33)($0.40)$14.80 million$14.68 millionViewN/AView Earnings Details
5/5/2016Q116($0.35)($0.36)$13.08 million$13.55 millionViewN/AView Earnings Details
3/10/2016Q415($0.30)($0.29)$14.45 million$14.04 millionViewListenView Earnings Details
11/5/2015Q315($0.33)($0.32)$12.72 million$12.33 millionViewListenView Earnings Details
8/13/2015Q215($0.31)($0.35)$12.23 million$11.90 millionViewListenView Earnings Details
5/14/2015Q115($0.37)($0.34)$10.83 million$11.20 millionViewListenView Earnings Details
3/19/2015Q414($0.33)($0.36)$11.83 million$12.20 millionViewN/AView Earnings Details
11/13/2014Q314($0.35)($0.37)$9.67 million$9.80 millionViewN/AView Earnings Details
8/13/2014Q214($0.33)($0.31)$9.36 million$8.70 millionViewN/AView Earnings Details
5/8/2014Q114($0.31)($0.32)$7.19 million$7.50 millionViewN/AView Earnings Details
3/18/2014Q4($0.38)($0.42)$6.43 million$6.84 millionViewListenView Earnings Details
11/25/2013Q313($6.59)$3.20 million$5.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Veracyte (NASDAQ:VCYT)
Current Year EPS Consensus Estimate: $-1.47 EPS
Next Year EPS Consensus Estimate: $-1.00 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.31)($0.31)($0.31)
Q2 20161($0.28)($0.28)($0.28)
Q3 20161($0.37)($0.37)($0.37)
Q4 20161($0.33)($0.33)($0.33)
(Data provided by Zacks Investment Research)


Dividend History for Veracyte (NASDAQ:VCYT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Veracyte (NASDAQ:VCYT)
Insider Ownership Percentage: 28.40%
Institutional Ownership Percentage: 55.31%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/3/2016Bonnie H AndersonCEOBuy5,000$5.40$27,000.00View SEC Filing  
6/1/2016Bonnie H AndersonCEOBuy5,000$5.46$27,300.00View SEC Filing  
5/31/2016Bonnie H AndersonCEOBuy2,500$5.46$13,650.00View SEC Filing  
11/25/2015Evan/ Fa JonesDirectorSell7,896$7.23$57,088.08View SEC Filing  
11/24/2015Evan/ Fa JonesDirectorSell7,104$7.20$51,148.80View SEC Filing  
7/22/2015Christopher M HallCOOSell2,500$11.85$29,625.00View SEC Filing  
6/26/2015Shelly D GuyerCFOSell1,000$12.08$12,080.00View SEC Filing  
9/10/2014Christopher M HallInsiderSell1,000$12.29$12,290.00View SEC Filing  
9/9/2014Evan/ Fa JonesDirectorSell27,304$12.60$344,030.40View SEC Filing  
8/18/2014Christopher M HallInsiderSell1,000$12.92$12,920.00View SEC Filing  
7/29/2014Julie BrooksEVPBuy1,122$14.69$16,482.18View SEC Filing  
7/28/2014Julie BrooksEVPBuy1,000$14.71$14,710.00View SEC Filing  
7/22/2014Julie BrooksVPBuy2,000$14.18$28,360.00View SEC Filing  
7/21/2014Julie BrooksVPBuy1,000$14.00$14,000.00View SEC Filing  
7/10/2014Christopher M HallInsiderSell3,000$14.92$44,760.00View SEC Filing  
6/27/2014Bonnie H AndersonCEOSell1,000$17.95$17,950.00View SEC Filing  
6/23/2014Bonnie H AndersonCEOSell4,000$16.45$65,800.00View SEC Filing  
6/23/2014Christopher M HallInsiderSell2,000$16.95$33,900.00View SEC Filing  
6/20/2014Shelly D GuyerCFOSell1,250$16.04$20,050.00View SEC Filing  
6/19/2014Christopher M HallInsiderSell3,000$14.99$44,970.00View SEC Filing  
6/12/2014Evan/ Fa JonesDirectorSell16,650$15.07$250,915.50View SEC Filing  
6/9/2014Evan/ Fa JonesDirectorSell22,870$14.57$333,215.90View SEC Filing  
6/5/2014Evan/ Fa JonesDirectorSell28,248$14.33$404,793.84View SEC Filing  
5/30/2014Evan/ Fa JonesDirectorSell23,882$15.33$366,111.06View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Veracyte (NASDAQ:VCYT)
News IconVeracyte announces new data suggesting ability of Afirma GEC in thyroid cancer diagnosis (NASDAQ:VCYT) - September 26 at 8:47 AM logoVeracyte (VCYT) Announces Positive Data on Afirma in Thyroid Cancer Diagnosis (NASDAQ:VCYT) - September 23 at 7:18 PM
News IconVeracyte Presents Data Demonstrating Potential to Enhance Afirma® Gene Expression Classifier Using an RNA Sequencing Platfor... (NASDAQ:VCYT) - September 23 at 7:18 PM logoVeracyte Presents Data Demonstrating Potential to Enhance Afirma® Gene Expression Classifier Using an RNA Sequencing Platform (NASDAQ:VCYT) - September 23 at 7:18 PM logoVeracyte (VCYT) Announces Palmetto GBA Posting of Draft LCD for Percepta Bronchial Genomic Classifier (NASDAQ:VCYT) - September 16 at 11:35 AM logoVeracyte Secures Draft Medicare Local Coverage Determination for Percepta® Bronchial Genomic Classifier from Palmetto GBA (NASDAQ:VCYT) - September 15 at 8:02 PM logoVeracyte (VCYT) to Present Afirma GEC Data at ATA Meeting (NASDAQ:VCYT) - September 15 at 11:42 AM logoVeracyte Announces Data from Seven Afirma® Gene Expression Classifier Studies to Be Presented at the 86th Annual Meeting of the American Thyroid Association (NASDAQ:VCYT) - September 15 at 11:42 AM
News IconNegative Day for Wall Street (NASDAQ:VCYT) - September 9 at 7:39 AM logoVeracyte (VCYT) Receives LCD from Major MAC for Percepta Bronchial Genomic Classifier (NASDAQ:VCYT) - September 8 at 7:35 PM logo7:38 am Veracyte announces that Noridian Healthcare Solutions has issued a draft local coverage determination for the Percepta Bronchial Genomic Classifier (NASDAQ:VCYT) - September 8 at 11:51 AM logoVeracyte Achieves Major Medicare Coverage Milestone for the Percepta® Classifier to Improve Lung Cancer Diagnosis (NASDAQ:VCYT) - September 8 at 11:51 AM logoVeracyte : to Present at Morgan Stanley Global Healthcare Conference (NASDAQ:VCYT) - August 30 at 7:50 PM logoVeracyte to Present at Morgan Stanley Global Healthcare Conference (NASDAQ:VCYT) - August 30 at 11:23 AM logoETF’s with exposure to Veracyte, Inc. : August 23, 2016 (NASDAQ:VCYT) - August 23 at 8:12 PM logoEdited Transcript of VCYT earnings conference call or presentation 3-Aug-16 8:30pm GMT (NASDAQ:VCYT) - August 19 at 7:53 PM logoVeracyte, Inc. :VCYT-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:VCYT) - August 12 at 11:24 AM logoVERACYTE, INC. Financials (NASDAQ:VCYT) - August 10 at 8:46 PM logoVeracyte Announces Second Quarter 2016 Financial Results (NASDAQ:VCYT) - August 4 at 11:23 AM logoVeracyte (VCYT) PT Lowered to $10 at Piper Jaffray Following Results (NASDAQ:VCYT) - August 4 at 11:23 AM logoPiper Jaffray Analyst Reiterates Overweight Rating on Shares of Veracyte Inc (VCYT) (NASDAQ:VCYT) - August 4 at 11:23 AM logoVeracyte reports 2Q loss (NASDAQ:VCYT) - August 3 at 8:29 PM logoQ2 2016 Veracyte Inc Earnings Release - After Market Close (NASDAQ:VCYT) - August 3 at 11:27 AM logoETF’s with exposure to Veracyte, Inc. : July 29, 2016 (NASDAQ:VCYT) - July 29 at 2:00 PM logoVeracyte to Host Conference Call and Webcast to Discuss Second Quarter 2016 Financial Results on Wednesday, August 3, 2016 (NASDAQ:VCYT) - July 12 at 8:33 AM logoVeracyte to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference (NASDAQ:VCYT) - June 30 at 10:48 AM logoVeracyte Named a San Francisco Bay Area 2016 "Top Workplace" (NASDAQ:VCYT) - June 27 at 7:30 AM logoVeracyte Now In Position For A Rate Increase In 2018 (NASDAQ:VCYT) - June 20 at 5:49 PM logoVeracyte Releases Statement on CMS's Final PAMA Rule (NASDAQ:VCYT) - June 17 at 7:19 PM logoNotable Tuesday Option Activity: CCOI, SWHC, VCYT (NASDAQ:VCYT) - June 15 at 7:29 AM logoVeracyte Announces Resignation of Its Chief Financial Officer (NASDAQ:VCYT) - June 13 at 4:19 PM logoVeracyte Statement on CMS's Preliminary Gapfill Rate for the Afirma® Gene Expression Classifier (NASDAQ:VCYT) - June 10 at 10:09 PM logoVeracyte to Present at the William Blair & Company 36th Annual Growth Stock Conference (NASDAQ:VCYT) - June 1 at 8:00 AM logoVeracyte (VCYT) to Present New Thyroid Cancer Diagnosis Data at AACE 2016 - (NASDAQ:VCYT) - May 27 at 1:43 PM
News IconBroker Roundup For Veracyte, Inc. (VCYT) - Share Trading News (NASDAQ:VCYT) - May 27 at 1:43 PM logoVeracyte Announces New Data that Advance Understanding of the Role of Gene Alterations In Thyroid Cancer Diagnosis (NASDAQ:VCYT) - May 27 at 7:47 AM logoVeracyte Announces Data from Multiple Studies Advancing Scientific Understanding of Thyroid Cancer to Be Presented at AACE Congress (NASDAQ:VCYT) - May 23 at 7:56 AM logoNew Data Suggesting Veracyte's Percepta® Bronchial Genomic Classifier Can Reduce Unnecessary Invasive Procedures In Lung Cancer Diagnosis Presented at ATS 2016 (NASDAQ:VCYT) - May 17 at 5:32 PM logoVeracyte, Inc. :VCYT-US: Earnings Analysis: Q1, 2016 By the Numbers (NASDAQ:VCYT) - May 17 at 4:28 PM logoVeracyte reports 1Q loss (NASDAQ:VCYT) - May 5 at 5:15 PM logoVeracyte Announces First Quarter 2016 Financial Results (NASDAQ:VCYT) - May 5 at 4:21 PM
News IconEarnings View for Veracyte, Inc. (NASDAQ:VCYT) - (NASDAQ:VCYT) - April 9 at 2:34 PM
News IconVeracyte, Inc. (VCYT) Updated Broker Price Targets - Share Trading News (NASDAQ:VCYT) - April 9 at 2:34 PM
News IconGhost Tree Capital buys $1.7 Million stake in Veracyte Inc (VCYT) - Everything HUDSON (NASDAQ:VCYT) - April 9 at 2:34 PM
News IconPiper Jaffray Exits Position in Veracyte Inc (VCYT) - Street Edition (NASDAQ:VCYT) - April 9 at 2:34 PM logoClinical Utility of Veracyte's Afirma® Gene Expression Classifier Demonstrated in Multiple Studies Presented at ENDO 2016 (NASDAQ:VCYT) - April 2 at 1:28 PM logoVERACYTE, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sh (NASDAQ:VCYT) - March 30 at 5:08 PM logoMultiple Studies Showcasing Clinical Utility of Veracyte's Afirma® Gene Expression Classifier to Be Presented at ENDO 2016 (NASDAQ:VCYT) - March 29 at 4:24 PM logoNew Data Show That Veracyte's Afirma® Gene Expression Classifier Reduces Unnecessary Thyroid Surgeries and Costs During Long-Term Follow-Up (NASDAQ:VCYT) - March 16 at 7:30 AM logoVERACYTE, INC. Files SEC form 10-K, Annual Report (NASDAQ:VCYT) - March 14 at 4:26 PM


Veracyte (NASDAQ:VCYT) Chart for Friday, September, 30, 2016

Last Updated on 9/30/2016 by Staff